BIO Submits Comments to the Illinois Department of Healthcare and Family Services Regarding its Proposed Rule Making Changes to 340B Program Reimbursement

Dear Ms. Badrov:

The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “Department”) proposed rule to amend 89 Ill. Adm. Code 140 regarding the 340B Drug Discount Program (the “Proposed Rule”). 

BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe. Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations. BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. In Illinois BIO works in collaboration with iBIO, whose membership includes strong representation from the bio-pharmaceutical sector. This sector accounts for a large portion of the $98 billion in biotech annual economic output and 369,000 directly and indirectly-created jobs in the state. 

To view the full comment letter, click here.